BR0314223A - Compostos fenil-indol para modular ige e inibir proliferação celular - Google Patents

Compostos fenil-indol para modular ige e inibir proliferação celular

Info

Publication number
BR0314223A
BR0314223A BR0314223-0A BR0314223A BR0314223A BR 0314223 A BR0314223 A BR 0314223A BR 0314223 A BR0314223 A BR 0314223A BR 0314223 A BR0314223 A BR 0314223A
Authority
BR
Brazil
Prior art keywords
cell proliferation
ige
inhibit cell
phenyl
indole compounds
Prior art date
Application number
BR0314223-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Jagadish C Sircar
Jailall Ramnauth
Mark L Richards
Original Assignee
Avanir Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avanir Pharmaceuticals filed Critical Avanir Pharmaceuticals
Publication of BR0314223A publication Critical patent/BR0314223A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/405Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14Radicals substituted by nitrogen atoms, not forming part of a nitro radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR0314223-0A 2002-09-12 2003-09-12 Compostos fenil-indol para modular ige e inibir proliferação celular BR0314223A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41077702P 2002-09-12 2002-09-12
PCT/US2003/030959 WO2004024896A2 (en) 2002-09-12 2003-09-12 Phenyl-indole compounds

Publications (1)

Publication Number Publication Date
BR0314223A true BR0314223A (pt) 2005-07-26

Family

ID=31994205

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0314223-0A BR0314223A (pt) 2002-09-12 2003-09-12 Compostos fenil-indol para modular ige e inibir proliferação celular

Country Status (16)

Country Link
US (1) US7375118B2 (enExample)
EP (1) EP1537079A4 (enExample)
JP (1) JP2006512293A (enExample)
KR (1) KR20050051658A (enExample)
CN (1) CN1694868A (enExample)
AR (1) AR041251A1 (enExample)
AU (2) AU2003270426A1 (enExample)
BR (1) BR0314223A (enExample)
CA (1) CA2498493A1 (enExample)
MX (1) MXJL05000009A (enExample)
PE (1) PE20050035A1 (enExample)
PL (1) PL375812A1 (enExample)
RU (1) RU2005109912A (enExample)
TW (1) TW200407303A (enExample)
WO (2) WO2004024655A2 (enExample)
ZA (1) ZA200502739B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6911462B2 (en) * 1998-05-22 2005-06-28 Avanir Pharmaceuticals Benzimidazole compounds for regulating IgE
CZ20032691A3 (en) * 2001-03-12 2004-04-14 Avanir Pharmaceuticals Benzimidazole compounds for modulating ige and inhibiting cellular proliferation
TW200304820A (en) * 2002-03-25 2003-10-16 Avanir Pharmaceuticals Use of benzimidazole analogs in the treatment of cell proliferation
WO2004024655A2 (en) * 2002-09-12 2004-03-25 Avanir Pharmaceuticals Phenyl-indole compounds for modulating ige and inhibiting cellular proliferation
TWI276631B (en) 2002-09-12 2007-03-21 Avanir Pharmaceuticals Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
EP1651198A2 (en) * 2003-08-08 2006-05-03 Avanir Pharmaceuticals Selective pharmacologic inhibition of protein trafficking and related methods of treating human diseases
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
WO2006019831A1 (en) 2004-07-14 2006-02-23 Ptc Therapeutics, Inc. Methods for treating hepatitis c
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
WO2006019832A1 (en) 2004-07-22 2006-02-23 Ptc Therapeutics, Inc. Thienopyridines for treating hepatitis c
ITMI20061368A1 (it) * 2006-07-14 2008-01-15 Acraf Composto 2-arilindolico sostituito in posizione 5, composizione farmaceutica che lo comprende nonche' composti intermedi e procedimento per prepararlo
CA2888369A1 (en) * 2012-10-17 2014-04-24 F. Hoffmann-La Roche Ag 6-aminoindole derivatives as trp channel antagonists
TWI752155B (zh) 2017-02-01 2022-01-11 德商菲尼克斯製藥股份有限公司 芳香烴受體(AhR)調節劑化合物
TWI674260B (zh) 2017-02-01 2019-10-11 德商菲尼克斯製藥股份有限公司 芳基烴受體(AhR)調節劑化合物
TW201835070A (zh) * 2017-02-21 2018-10-01 德商菲尼克斯製藥股份有限公司 芳香烴受體(AhR)調節劑化合物
ES2984415T3 (es) * 2017-12-12 2024-10-29 Kamada Ltd Métodos para inducir tolerancia inmunitaria y reducir la respuesta de anticuerpos anti-fármaco
EP3867280A4 (en) * 2018-10-18 2022-11-09 Sinomab Bioscience Limited METHODS OF TREATMENT OF RHEUMATOID ARTHRITIS
MX2022013797A (es) 2020-05-08 2022-11-30 Genmab As Anticuerpos biespecificos contra cd3 y cd20.
WO2022040341A1 (en) * 2020-08-20 2022-02-24 The Board Of Trustees Of The Leland Stanford Junior University Abscopal therapy for cancer
KR20230066040A (ko) 2020-09-10 2023-05-12 젠맵 에이/에스 만성 림프구성 백혈병을 치료하기 위한 cd3 및 cd20에 대한 이중특이적 항체
CN116782933A (zh) 2020-09-10 2023-09-19 健玛保 用于治疗弥漫性大b细胞淋巴瘤的联合疗法中的针对cd3和cd20的双特异性抗体
CA3189883A1 (en) 2020-09-10 2022-03-17 Brian Elliott Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphoma
CA3190376A1 (en) 2020-09-10 2022-03-17 Brian Elliott Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphoma
US20240034812A1 (en) 2020-09-10 2024-02-01 Genmab A/S Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
AR133526A1 (es) * 2023-08-09 2025-10-08 Daewoong Pharmaceutical Co Ltd Nuevo compuesto, y una composición farmacéutica para la prevención o el tratamiento del cáncer o tumores que comprende el mismo
US20250275978A1 (en) * 2024-03-04 2025-09-04 Cardiff Oncology, Inc. Use of onvansertib as monotherapy and in combination with cetuximab in treating ras wild-type colorectal cancer

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3224512A1 (de) 1982-07-01 1984-01-05 Dr. Karl Thomae Gmbh, 7950 Biberach Neue imidazolderivate, ihre herstellung und diese verbindungen enthaltende arzneimittel
US4510158A (en) 1984-03-05 1985-04-09 Sterling Drug Inc. 2-Phenylindole derivatives, their use as complement inhibitors
JPS62501572A (ja) 1985-05-03 1987-06-25 ザ・フォックスボロ・カンパニ− 蒸留カットポイントの制御
US4939133A (en) 1985-10-01 1990-07-03 Warner-Lambert Company N-substituted-2-hydroxy-α-oxo-benzeneacetamides and pharmaceutical compositions having activity as modulators of the arachidonic acid cascade
LU86258A1 (fr) 1986-01-21 1987-09-03 Rech Dermatologiques C I R D S Composes benzamido aromatique,leur procede de preparation et leur utilisation en medecine humaine ou veterinaire et en cosmetique
US5206257A (en) 1987-03-05 1993-04-27 May & Baker Limited Pesticidal method using 2-phenylimidazole derivatives
JP2630432B2 (ja) 1987-08-24 1997-07-16 コニカ株式会社 新規なシアンカプラーを含有するハロゲン化銀カラー写真感光材料
DE68908431T2 (de) 1988-02-02 1993-12-23 Schering Biotech Corp Methode zur Verminderung der Immunglobulin-E-Reaktion.
JP2700475B2 (ja) 1988-07-30 1998-01-21 コニカ株式会社 非線形光学材料および非線形光学素子
IT1232252B (it) 1989-02-22 1992-01-28 Rotta Research Lab Derivati della n fenil benzamide ad attivita' antiulcera ed antiallerica e procedimento per la loro preparazione
FR2643903A1 (fr) 1989-03-03 1990-09-07 Union Pharma Scient Appl Nouveaux derives de benzimidazole, leurs procedes de preparation, intermediaires de synthese, compositions pharmaceutiques les contenant, utiles notamment pour le traitement des maladies cardiovasculaires, et des ulceres duodenaux
EP0415886A3 (en) 1989-08-30 1991-10-23 Ciba-Geigy Ag Aza compounds
FR2658511B1 (fr) 1990-02-16 1992-06-19 Union Pharma Scient Appl Nouveaux derives de benzimidazole et d'azabenzimidazole, antagonistes des recepteurs au thromboxane; leurs procedes de preparation, compositions pharmaceutiques les contenant.
WO1992002500A1 (fr) 1990-07-31 1992-02-20 Teikoku Hormone Mfg. Co., Ltd. Derive de 2-phenylindole
EP0469477B1 (en) 1990-08-02 1995-09-20 F. Hoffmann-La Roche Ag Antiallergic combination
US5633377A (en) 1990-12-28 1997-05-27 Neurogen Corporation 4-piperidino- and piperazinomethyl-2-cyclohexyl imidazole derivatives; dopamine receptor subtype specific ligands
JPH06263993A (ja) 1991-01-21 1994-09-20 Konica Corp アゾメチン系染料、インドアニリン系染料及びインドフェノール系染料の製造法
IE71647B1 (en) 1991-01-28 1997-02-26 Rhone Poulenc Rorer Ltd Benzamide derivatives
ES2102036T3 (es) 1992-06-15 1997-07-16 Celltech Therapeutics Ltd Derivados con grupo fenilo trisustituido utilizados como inhibidores selectivos de la fosfodiesterasa iv.
US5322847A (en) 1992-11-05 1994-06-21 Pfizer Inc. Azabenzimidazoles in the treatment of asthma, arthritis and related diseases
PE27997A1 (es) 1994-04-29 1997-09-20 Lilly Co Eli Antagonistas de receptores de taquicininas
US5643893A (en) 1994-06-22 1997-07-01 Macronex, Inc. N-substituted-(Dihydroxyboryl)alkyl purine, indole and pyrimidine derivatives, useful as inhibitors of inflammatory cytokines
DE4426625A1 (de) 1994-07-27 1996-03-14 Schering Ag 2-Phenylindole, Verfahren zu deren Herstellung, diese enthaltende pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln
US5496826A (en) 1994-09-02 1996-03-05 Bristol-Myers Squibb Company Pharmaceutical methods of using heterocyclic derivatives of N-phenylamides
US5821258A (en) 1994-12-27 1998-10-13 Mitsui Chemicals, Inc. Phenylbenzimidazole derivatives
DE19503160A1 (de) 1995-02-01 1996-08-08 Bayer Ag Verwendung von Phenylcyclohexylcarbonsäureamiden
EP0841924B1 (en) 1995-08-02 2002-10-02 Newcastle University Ventures Limited Benzimidazole compounds
US6387938B1 (en) 1996-07-05 2002-05-14 Mochida Pharmaceutical Co., Ltd. Benzimidazole derivatives
TW467902B (en) 1996-07-31 2001-12-11 Bristol Myers Squibb Co Diphenyl heterocycles as potassium channel modulators
US6153631A (en) 1996-10-23 2000-11-28 Zymogenetics, Inc. Compositions and methods for treating bone deficit conditions
WO1998017267A1 (en) 1996-10-23 1998-04-30 Zymogenetics, Inc. Compositions and methods for treating bone deficit conditions
CA2232467A1 (en) 1997-03-20 1998-09-20 Richard A. Glennon Imidazoles with serotonin receptor binding activity
US6034256A (en) 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
BR9810745A (pt) 1997-06-10 2001-03-13 Glaxo Group Ltd Derivados de benzimidazol
GB9718833D0 (en) 1997-09-04 1997-11-12 Merck Sharp & Dohme Therapeutic agents
HUP0004024A3 (en) 1997-09-26 2001-10-29 Zentaris Gmbh Azabenzimidazole-based compounds, process for their preparation and pharmaceutical composition thereof
US6100282A (en) 1998-01-02 2000-08-08 Hoffman-La Roche Inc. Thiazole derivatives
US6919366B2 (en) 1998-05-22 2005-07-19 Avanir Pharmaceuticals Benzimidazole derivatives as modulators of IgE
BR9910642A (pt) 1998-05-22 2001-10-09 Avanir Pharmaceuticals Análogos de benzimidazol como reguladores descendentes de ige
US6303645B1 (en) 1998-05-22 2001-10-16 Avanir Pharmaceuticals Benzimidazole derivatives as modulators of IgE
US6911462B2 (en) 1998-05-22 2005-06-28 Avanir Pharmaceuticals Benzimidazole compounds for regulating IgE
US6369091B1 (en) 1998-05-22 2002-04-09 Avanir Pharmaceuticals Benzimidazole analogs as down-regulators of IgE
JP2000095767A (ja) 1998-09-28 2000-04-04 Takeda Chem Ind Ltd 性腺刺激ホルモン放出ホルモン拮抗剤
HK1041483B (zh) 1998-10-23 2004-12-24 霍夫曼-拉罗奇有限公司 雙環氮雜環
IL142917A0 (en) 1998-11-03 2002-04-21 Basf Ag Substituted 2-phenylbenzimidazoles, the production thereof and their use
HRP20010451A2 (en) 1998-11-17 2003-04-30 Basf Ag 2-phenylbenzimidazoles and 2-phenylindoles, and production and use thereof
TR200101498T2 (tr) 1998-11-27 2001-11-21 Basf Aktiengesellschaft İkameli benzimidazoller ve parp inhibitörleri olarak kullanımları
DE19918211A1 (de) 1999-04-22 2000-10-26 Basf Ag Cycloalkylsubstituierte Benzimidazole, deren Herstellung und Anwendung
DE19920936A1 (de) 1999-05-07 2000-11-09 Basf Ag Heterozyklisch substituierte Benzimidazole, deren Herstellung und Anwendung
US6423734B1 (en) 1999-08-13 2002-07-23 The Procter & Gamble Company Method of preventing cancer
DE19939463A1 (de) 1999-08-20 2001-02-22 Boehringer Ingelheim Pharma Aminocarbonyl-substituierte Benzimidazolderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US6759425B2 (en) 1999-10-21 2004-07-06 Avanir Pharmaceuticals Benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
US6242461B1 (en) 2000-01-25 2001-06-05 Pfizer Inc. Use of aryl substituted azabenzimidazoles in the treatment of HIV and AIDS related diseases
GB0007405D0 (en) 2000-03-27 2000-05-17 Smithkline Beecham Corp Compounds
US6537994B2 (en) 2000-07-17 2003-03-25 Wyeth Heterocyclic β3 adrenergic receptor agonists
US6777442B2 (en) 2001-03-12 2004-08-17 Bayer Aktiengesellschaft Diphenyl derivatives
BRPI0208075B8 (pt) 2001-03-12 2021-05-25 Janssen Pharmaceutica Nv processo para a preparação de compostos de imidazol
CZ20032691A3 (en) 2001-03-12 2004-04-14 Avanir Pharmaceuticals Benzimidazole compounds for modulating ige and inhibiting cellular proliferation
TW200304820A (en) 2002-03-25 2003-10-16 Avanir Pharmaceuticals Use of benzimidazole analogs in the treatment of cell proliferation
TWI276631B (en) 2002-09-12 2007-03-21 Avanir Pharmaceuticals Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
WO2004024655A2 (en) * 2002-09-12 2004-03-25 Avanir Pharmaceuticals Phenyl-indole compounds for modulating ige and inhibiting cellular proliferation
RU2005134670A (ru) 2003-04-10 2006-06-10 Аванир Фармасьютикалс (Us) Производные имидазола для лечения аллергических и гиперпролиферативных нарушений
EP1651198A2 (en) 2003-08-08 2006-05-03 Avanir Pharmaceuticals Selective pharmacologic inhibition of protein trafficking and related methods of treating human diseases

Also Published As

Publication number Publication date
CA2498493A1 (en) 2004-03-25
MXJL05000009A (es) 2005-06-07
WO2004024896A3 (en) 2004-06-24
AU2003270426A1 (en) 2004-04-30
EP1537079A4 (en) 2007-05-16
PE20050035A1 (es) 2005-01-24
US20040180946A1 (en) 2004-09-16
AU2003277152A1 (en) 2004-04-30
EP1537079A2 (en) 2005-06-08
WO2004024655A2 (en) 2004-03-25
KR20050051658A (ko) 2005-06-01
CN1694868A (zh) 2005-11-09
JP2006512293A (ja) 2006-04-13
PL375812A1 (en) 2005-12-12
RU2005109912A (ru) 2006-04-27
US7375118B2 (en) 2008-05-20
TW200407303A (en) 2004-05-16
WO2004024896A2 (en) 2004-03-25
AR041251A1 (es) 2005-05-11
ZA200502739B (en) 2005-10-13

Similar Documents

Publication Publication Date Title
BR0314223A (pt) Compostos fenil-indol para modular ige e inibir proliferação celular
BR0314235A (pt) Compostos de fenil-aza-benzimidazol para modulação de ige e inibição da proliferação celular
BR0208010A (pt) Composto de benzimidazol para modulação de ige e inibição de proliferação celular
BR9910641A (pt) Derivados de benzimidazol como moduladores de ige
BR112022022524A2 (pt) Proteínas imunomoduladoras inibidoras de april e baff com e sem uma proteína inibidora de células t e métodos de uso das mesmas
BRPI0409097A (pt) derivados de imidazol para tratamento de distúrbios alérgicos e hiperproliferativos
MA31167B1 (fr) Inhibiteurs de l'activite de akt
BRPI0517015A (pt) compostos e composições como inibidores de atividade de receptor 1 de canabinóide
CY1115188T1 (el) Πολυκυκλικες ετεροαρυλ-υποκατεστημενες τριαζολες χρησιμες ως αναστολεις του axl
CY1116754T1 (el) Παραγωγα νιτροκατεχολης ως αναστολεις της comt
MY142589A (en) Benzimidazole derivatives : preparation and pharmaceutical applications
BR0316606A (pt) Derivados de aminoindazóis e sua utilização como inibidores de quinases
ATE230394T1 (de) Indolderivate und deren verwendung zur behandlung von malignen und anderen, auf pathologischen zellproliferationen beruhenden erkrankungen
NO20052028L (no) Pyridinderivater som CB2 reseptor modulatorer
BRPI0607927A2 (pt) derivados de pirazol-pirimidina
BRPI0512352A (pt) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimiocinas
BRPI0411364A (pt) compostos tendo atividade inibidora de fosfatidilinositol 3-cinase e métodos de uso dos mesmos
ATE448189T1 (de) Glycerin-peg-derivate als inhibitoren der cyclooxigenase-2 und der phospholipase-a2
ATE410408T1 (de) Von aminosäuren abgeleitete prodrugs von propofolzusammensetzungen und anwendungen davon
ATE290857T1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
DE69942575D1 (de) Nukleinsäuremolekül, die für die alpha-kettedes pferde-fc-epsilon-rezeptors kodieren, korrespondierende proteine und ihre verwendungen
ATE291621T1 (de) Nukleinsaeuren und proteine der katze fc-epsilon rezeptor alpha-kette und deren verwendungen
BRPI0416994A (pt) inibidores de proteìna cinase com base em indolinona avançada
BRPI0408778A (pt) proteìnas ativadoras de elemento de resposta à amp cìclica e uso relacionado as mesmas
BRPI0607560A2 (pt) derivados de tienopiridina e o uso dos mesmos como moduladores de hsp90

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A , 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2069 DE 31/08/2010.